Tagged with R

France France is betting big on industrial transformation. With its sweeping EUR 54 billion France 2030 investment plan, the government has laid down a clear ambition: to become a global leader in innovation and industrial competitiveness. While foreign investment is flowing in, and biomedicine production is robust, local pharma industry leaders…

Americas In a world where medical innovation is accelerating, Latin America–a region of some 662 million people—is falling dangerously behind. Patients face wait times of up to 5.6 years to access life-saving therapies already available elsewhere. This is not merely a delay, but a systemic failure rooted in chronic underinvestment and…

Switzerland Dr. Olivier Michielin serves as Head of Oncology at Geneva University Hospital (HUG) and Head of the Division of Precision Oncology, whilst maintaining his professorship at the University of Geneva as well as the École Polytechnique Fédérale de Lausanne (EPFL). A co-director of the Swiss Cancer Centre Leman, Dr. Michelin…

Denmark At first glance, Denmark might seem an unlikely hub for pharmaceutical production. With its small size and some of the highest labour costs in Europe, manufacturers might decide to look elsewhere. Yet major global players like Fujifilm Biotechnologies and AGC Biologics are doubling down on their Danish investments, expanding facilities…

Denmark Morten Graugaard, former partner at Novo Holdings A/S, a global life science investment fund, became CEO of Orbis Medicine in February 2025. Drawing on his deep experience in life sciences and venture capital, he has led the company to raise EUR 116 million in funding, positioning Orbis as a pioneer…

Denmark Leading GN’s Hearing division with over a decade of insight and hands-on experience, Peter Justesen has overseen the company’s evolution into a more integrated, globally attuned, and innovation-led organisation. In this conversation, he reflects on the group’s transformation, the technological frontiers of hearing care, and the urgency of reframing hearing…

Denmark After years abroad, Radiometer’s President and CEO, Francis Van Parys, returned to Europe to lead one of Denmark’s most historic MedTech companies into its next chapter. In this interview, he discusses how Radiometer is redefining its role, moving beyond instrumentation to become a driver of time-sensitive clinical decisions through digital…

Switzerland Pharmaceutical manufacturing is evolving into a strategic pillar of competitiveness, shaped by modular design, digital integration, and a growing focus on long-term efficiency. Bilfinger, through its Technology segment, is playing a central role in this transformation, supporting clients across biopharma, energy transition, and nuclear with scalable, future-ready solutions. In this…

Colombia Clara Isabel Rodríguez, Executive Director of the Colombian Association of the Pharmaceutical Industry (ASCIF), shares her journey from public sector leadership to industry advocacy. With deep experience in health regulation and public administration, Rodríguez reflects on Colombia’s pharma landscape, the challenges of ongoing health reform, and why local manufacturing is…

Argentina Juan Jose Marconi, Executive Director of Cooperala, offers a unique perspective shaped by decades of leadership across Argentina’s pharmaceutical and healthcare sectors. With a strong academic background in applied mathematics, industrial engineering, and economics, Marconi has led both major pharmaceutical companies and national healthcare institutions. Since 2021, he has been…

Brazil Brazil’s pharmaceutical sector is undergoing a quiet but significant transformation. Once dominated by multinationals and focused largely on generics, a group of leading domestic players is now charting a different course, towards innovation, manufacturing sovereignty, and strategic influence. Speaking on behalf of Grupo FarmaBrasil, a coalition of the country’s top…

Japan Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) concluded FY 2024‑25 (April 2024–March 2025) with a total of 148 approval decisions, including no less than 66 new active ingredients and 82 lifecycle updates, including new indications, pediatric expansions, and formulation changes. Innovation Snapshot A steady stream of orphan and rare‑disease designations—including sparsentan for primary…